Pitt Gets $20 Million for Research from Institute for Transfusion Medicine’s Blood Science Foundation
PITTSBURGH, July 20, 2015
– University of Pittsburgh officials announced today that its Vascular Medicine Institute
has received a new commitment of $15 million over the next 10 years from the Institute for Transfusion Medicine’s (ITxM) Blood Science Foundation
, as well as an additional $5 million to establish the Institute for Transfusion Medicine Research Endowment. Funding from ITxM’s Blood Science Foundation and Hemophilia Center of Western Pennsylvania now totals $50 million since 2008.
“We are proud to celebrate this remarkable partnership and grateful that these organizations – working together – have enabled the University to take some bold steps in the past years to advance our research in vascular medicine and bring a new level of care to the people of our region and beyond,” said Pitt Chancellor Patrick Gallagher. “This is an extraordinary gift that will be a springboard to draw in other funding from the National Institutes of Health and other national organizations.”
“The tools and knowledge at our disposal have never been greater or more powerful, and their availability converges with a time of great need in this country,” said Arthur S. Levine, M.D., Pitt’s senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of Medicine. “This generous support will help us seize the moment to seek solutions and provide answers.”
Such support has allowed the recruitment and support of outstanding investigators who are experts in vascular biology, red cell and platelet biology, and hemostasis and thrombosis research, all focused on understanding human vascular and blood diseases and developing new targeted therapies, noted VMI Director and Distinguished Professor Mark Gladwin, M.D., who also is the Dr. Jack D. Myers Professor of Internal Medicine and chair of the Department of Medicine, Pitt School of Medicine.
“This assistance also has supported the training of young investigators focused on blood and cardiovascular diseases,” he added. “We anticipate that the study of vascular biology will enable the development of new therapies and interventions for a multitude of vascular conditions, such as sickle cell disease, diabetes, coronary artery disease and hemophilia.”
“Research is one of the key pillars of our strategic plan and I cannot think of a more appropriate way for ITxM to execute on both our mission and strategy. It is an honor for us to be able to provide ongoing support for the Vascular Medicine Institute at the University of Pittsburgh, partnering to develop innovative therapies to improve the quality of life for people with blood related disorders,” said James P. Covert, ITxM president and chief executive officer.
In celebration of the gift, as well as a $5 million match from the University of Pittsburgh Physicians group for the ITxM Research Endowment, a private dinner will be held on Monday, July 20, at Alumni Hall in Oakland.